Researchers are developing what they hope will be the first successful vaccine against the highly contagious and difficult-to ...

The discovery of the first mRNA-stabilizing substance could pave the way for groundbreaking advancements in the development ...

Study reveals single-chain mRNA vaccines confer 100% protection against lethal mpox challenge in mice, marking a significant ...

Northwestern filed a lawsuit against Moderna Wednesday alleging the company misused the University’s patented lipid ...

In an era where viral outbreaks can escalate into global pandemics with alarming speed, the ability to quickly develop new ...

In one of our recent articles about 10 High Growth Non-Tech Stocks That Are Profitable in 2024, we talked about how the US ...

An 800% increase in licensing deal values indicates growing confidence in mRNA technology, but some vaccine producers are ...

We recently compiled a list of the 10 Worst Performing NASDAQ Stocks in 2024. In this article, we are going to take a look at ...

At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II dose-ranging trial for mRNA-1403, a vaccine ...

Discover why the stock prices of mRNA therapy creators BioNTech and Moderna have plummeted and whether they are still worth ...

Revaccination at 12 months with the investigational respiratory syncytial virus (RSV) vaccine mRNA-1345 is well tolerated and supported for eligible older adults, according to study results presented ...

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...